UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 1, 2016
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36508 | 27-1524986 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 2225 Colorado Avenue Santa Monica, California |
90404 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(310) 824-9999
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On June 1, 2016, Kite Pharma, Inc. (the “Company”) held its Annual Meeting of Stockholders at the Company’s offices, located at 2355 Utah Avenue, El Segundo, California 90245 at 8:30 a.m. local time (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 21, 2016. The following is a brief description of each matter voted upon, and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.
Each of the three nominees for Class II directors was elected to serve on the Company’s Board of Directors (the “Board”) until the Annual Meeting of Stockholders in 2019 or until his or her respective successor has been duly elected or qualified. The voting results were as follows:
| Director Name |
Votes For | Votes Withheld |
Broker Non-Votes |
|||||||||
| Ms. Farah Champsi |
31,815,582 | 70,304 | 8,555,899 | |||||||||
| Mr. Roy Doumani |
25,014,038 | 6,871,848 | 8,555,899 | |||||||||
| Mr. Ran Nussbaum |
31,796,429 | 89,457 | 8,555,899 | |||||||||
The Company’s stockholders ratified the selection by the Audit Committee of the Board of Ernst &Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016. The voting results were as follows:
| Votes For |
Votes Against |
Abstentions |
Broker Non-Votes | |||
| 39,507,950 | 886,663 | 47,172 | 0 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KITE PHARMA, INC. (Registrant) | ||||
| Dated: June 6, 2016 | By: | /s/ Paul Jenkinson | ||
| Name: | Paul Jenkinson | |||
| Title: | Chief Financial Officer | |||